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Porphyromonas gingivalis is a member of the dysbiotic oral microbiome and a “keystone pathogen” that 
causes severe periodontal disease, which is among the most prevalent infectious diseases. Part of the 
virulence factors secreted by P. gingivalis are the essential cysteine peptidases gingipain K (Kgp) and R 
(RgpA and RgpB), which account for 85% of the extracellular proteolytic activity of the pathogen and 
are thus prime targets for inhibition. We report the high-resolution (1.20 Å) complex structure of Kgp 
with KYT-36, a peptide-derived, potent, bioavailable and highly selective inhibitor, which is widely used 
for studies in vitro, in cells and in vivo. Sub-nanomolar inhibition of Kgp is achieved by tight binding 
to the active-site cleft, which is covered for its sub-sites S3 through s1’ under establishment of nine 
hydrophobic interactions, 14 hydrogen bonds and one salt bridge. In addition, an inhibitor carbonyl 
carbon that mimics the scissile carbonyl of substrates is pyramidalized and just 2.02 Å away from the 
catalytic nucleophile of Kgp, C477sγ. Thus, the crystal structure emulates a reaction intermediate of the 
first nucleophilic attack during catalysis of cysteine peptidases. The present study sets the pace for the 
development of tailored next-generation drugs to tackle P. gingivalis.
The human oral microbiome is extraordinarily diverse and includes phages, viruses, archaea, bacteria, fungi, 
and protozoa1. Bacteria are represented by ~1000 different species at 108–109 bacteria per mL saliva or mg dental 
plaque, which makes the oral microbiome second only to the colon microbiome in complexity2. Oral bacteria 
mainly belong to the phyla Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, Spirochaetes, Synergistetes 
and Tenericutes, and they divide into commensal and dysbiotic. While the former are usually beneficial to the 
host, the latter are associated with disease due to changes in microbiome composition and functional activities3. 
Dysbiotic bacteria are mostly Gram-negative and anaerobic, and they are responsible for two of the most wide-
spread human diseases: dental caries and periodontal disease (PD). These are not classical infectious diseases 
originated by single pathogens but have polymicrobial origins and result from a combination of microbiota rela-
tionships, host susceptibility, and environmental factors, such as smoking and diet1,4. In particular, PD is the sixth 
most prevalent disabling health condition and affects an estimated ~750 million people worldwide5. It causes 
alveolar bone resorption, formation of deep periodontal pockets, and tooth loosening, and is epidemiologically 
associated with several systemic diseases including atherosclerosis, diabetes and cardiovascular conditions6. PD 
derives from an exacerbated inflammatory response to normal microbiota triggered by the presence of dysbiotic 
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species including Aggregatibacter (formerly Actinobacillus) actinomycetemcomitans, Fusobacterium nucleatum, 
Prevotella intermedia, Treponema denticola, Tannerella forsythia and Porphyromonas gingivalis. For many years, 
the latter three species were englobed in the “red complex,” which substantially contributes to the subgingival 
biofilm and plaque and is intimately associated with severe forms of PD7. Among these species, P. gingivalis is a 
“keystone pathogen,” which converts other benign members of the biofilm into pathobionts and causes aggressive 
damage to periodontal tissues8. To this aim, it employs an armamentarium of virulence factors, which further 
contribute to pathogenesis by deregulating immune and inflammatory responses in the host.
P. gingivalis virulence factors include peptidases, which break down proteins within infected tissues, thus 
nourishing bacteria and facilitating their dissemination and host colonization9. Peptidases also dismantle host 
defenses and outcompete bacterial competitors within periodontal pockets10. The most relevant are the cysteine 
peptidases gingipain K (alias Kgp) and R (RgpA and RgpB), which cleave proteins and peptides after lysines 
and arginines, respectively11. They are translocated from the periplasm across the outer membrane layer to the 
extracellular space through a type-IX secretion system, which consists of at least 18 proteins, some of which are 
engaged in post-translational modification of cargo proteins12,13. The signal for translocation is a C-terminal 
domain conserved across cargos, which in RgpB adopts an immunoglobulin-like fold encompassing seven 
antiparallel β-strands organized in a β-sandwich14.
Gingipains are detected at concentrations exceeding 100 nM15 in gingival crevicular fluid from P. 
gingivalis-infected periodontitis sites, where they account for 85% of the total extracellular proteolytic activ-
ity of the bacterium16,17. Kgp, which is responsible for most of this activity18, is a 1723/1732-residue multid-
omain enzyme encompassing an N-terminal signal peptide, a pro-domain for latency, a caspase-like cysteine 
peptidase catalytic domain (CD), an immunoglobulin superfamily-like domain (IgSF), between three and five 
hemagglutinin-adhesion domains, and the C-terminal domain for type-IX secretion19. Kgp degrades connec-
tive tissue and plasma proteins, for example heme- and hemoglobin-transporting proteins, fibrinogen, fibronec-
tin, plasma kallikrein, immunoglobulins, as well as peptidase inhibitors, thus causing vascular permeability and 
bleeding19,20. Kgp is indispensable for bacterial survival and the outcome of PD16,18, and has thus been hailed as 
a prime target for the development of novel drugs to treat PD19,21,22. This is of particular importance given that 
the current standard treatment of PD includes mechanical debridement and the widespread use of antibiotics 
and disinfectants, which have serious adverse effects due to toxicity and the development of bacterial resistance. 
Moreover, this treatment does not guarantee disease eradication23.
While a lot of effort has been dedicated lately to phylogenetic associations and meta-omics of the oral micro-
biome24,25, molecular and functional studies to discover valid biomarkers of oral pathophysiology, understand 
host–microbiome interactions, and develop novel drugs have largely been neglected1. An exception is the drug 
precursor candidate KYT-36 (Fig. 1), a peptide-derived, small-molecule inhibitor developed in 2004 in the labo-
ratory of Kenji Yamamoto26. It is very specific for and potent against Kgp (Ki ≈ 10−10 M). Together with inhibitor 
KYT-1, which specifically tackles RgpA and RgpB, it strongly inhibited degradation of host proteins in culture 
supernatants and abolished thriving of P. gingivalis in cell cultures and in periodontal pockets in vivo. Moreover, it 
prevented Kgp-triggered vascular permeability in guinea pigs, i.e. demonstrating its efficacy against bacterial vir-
ulence in vivo, with no toxicity effects at the doses tested19. Based on these properties, the molecule and its deriv-
atives are subject of patents by Cortexyme, Inc. for the therapeutic treatment of P. gingivalis (US20160096830A1, 
US2017014468A1 and WO2017201322A1) and by others (JP2010270061A and JP4982908B2). KYT-36 is cur-
rently distributed by at least four companies (Peptides International, www.pepnet.com; Pepta Nova, peptanova.
de; MyBioSource, www.mybiosource.com; and Peptide Institute, www.peptide.co.jp) and has been used for years 
as the Kgp inhibitor of reference for studies in vitro, in cells and in vivo (see21,22,27 for examples).
Figure 1. Chemical structure of KYT-36. The inhibitor, with IUPAC name benzyl-N-[(2S)-1-[[(3S)-7-amino-
1-(benzylamino)-1,2-dioxoheptan-3-yl]amino]-5-(2-methyl-2-phenylhydrazinyl)-1,5-dioxopentan-2-yl]
carbamate, consists of benzyloxycarbonyl (BOC), L-glutaminyl (GLN), methylphenylamino (MPA), L-lysinyl 
(LYS), and benzylcarbamoyl (BCA) moieties. A black arrow indicates the carbonyl mimicking the scissile 
carbonyl of a substrate. The molecular mass of the dichloride salt is 703.7 Da.
3Scientific RepoRts |          (2019) 9:4935  | https://doi.org/10.1038/s41598-019-41354-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Whilst the efficacy of KYT-36 is well established, no information is available on its chemical mechanism of 
inhibition. This information is provided by three-dimensional structural studies, which are part of rational drug 
design strategies28,29. To this aim, we recently determined the crystal structure of the CD and IgSF domains of 
Kgp30 and of their zymogenic complex with the pro-domain31. These results revealed the mechanisms of action 
and latency of this peptidase. Here, we analyzed the crystal structure of Kgp from P. gingivalis strain W83 in 
complex with KYT-36 to very high resolution (1.20 Å). This is the first complex structure of the major proteolytic 
virulence factor of the periodontal pathogen reported with a drug or lead compound.
Results and Discussion
Structure of the Kgp catalytic domain. The Kgp fragment analyzed encompassed domains CD (resi-
dues D229-P600) and IgSF (K601-P683). Taken together, these domains form an elongated structure that resembles 
a tooth: the CD forms the crown with the cusp at its top, and the IgSF, which is a six-stranded antiparallel open 
β-barrel, shapes the root (see Fig. 2A). The CD is subdivided into an N-terminal subdomain (NSD; D229-K375) and 
a C-terminal subdomain (CSD; S376-P600), which are laterally attached to each other. Each of these subdomains 
is an α/β/α-sandwich consisting of a central β-sheet flanked by α-helices on either side. In NSD, the sheet is 
four-stranded and parallel; in CSD, it is six-stranded and parallel for all strands except the outermost strand at 
the interface with NSD, which is antiparallel to all other strands. In this way, the overall structure spans a central 
pseudo-continuous ten-stranded β-sheet. The NSD further contains two and three helices on either side of the 
sheet, respectively, plus an inserted β-ribbon and a calcium-binding site with structural functions. The CSD con-
tains five and four helices on either side of the sheet, respectively, plus a β-ribbon and two sodium-binding sites. A 
second calcium site is found at the NSD-CSD interface. For further structural details on the general architecture 
of Kgp, see30.
The active-site cleft of Kgp is found at the tooth cusp, on the CSD surface (Fig. 2A,B). As common in 
α/β-hydrolase-enzymes, residues engaged in substrate binding and catalysis come from loops that link strands of 
the central β-sheet on its the C-terminal edge32. As found in other cysteine peptidases33, Kgp probably contains 
a catalytic triad (C477, H444 and D388), which may form a charge-relay system for catalysis19,30,34. Atom C477Sγ 
acts as the nucleophile that attacks the scissile carbonyl carbon of substrates, which in a first step proceeds over 
a covalent tetrahedral reaction intermediate to an acyl-enzyme thioester complex with concomitant release of 
the amine reaction product35. In a second step, the covalent acyl-enzyme is hydrolyzed by a solvent molecule 
to release the acyl reaction product. In Kgp, substrates are bound with a lysine intruding the specificity pocket 
(sub-site S1) of the active-site cleft (for substrate and enzyme sub-site nomenclature, see36). The bottom of the 
specificity pocket leads to an internal water channel, which extends across the CSD to the opposite outer surface 
of the subdomain30.
The Kgp·KYT-36 complex. The complex structure was determined to very high resolution (1.20 Å; 
Fig. 2C,D), which enabled us to unambiguously assign the molecular determinants that cause sub-nanomolar 
inhibition of Kgp (Fig. 2B,E). KYT-36 is a L-peptide-derived molecule that mimics a substrate binding in 
extended conformation to cleft sub-sites S3, S2, S1 and S1’ (Fig. 2B). It can be divided into five moieties: BOC, 
GLN, MPA, LYS and BCA (Fig. 1).
The BOC benzyl group nestles in a hydrophobic pocket created by the side chains of H575 and W391, which 
together with Y512 and W513 create a shallow S3 sub-site in Kgp. The BOC carbonyl, which imitates the eponymous 
group of a substrate residue in position P3, is hydrogen-bonded to W513N (Fig. 2E). Downstream moiety GLN is 
in S2 and thus protrudes into the bulk solvent. Its side chain is folded towards the primed side of the cleft and its 
main-chain carbonyl establishes solvent-mediated hydrogen-bonds with H444Nε2, D388Oδ2, and W513Nε1. The 
aliphatic part of its side chain interacts with Y512 and its side-chain carboxamide performs an intramolecular 
hydrogen bond via the nitrogen with the carbonyl of the downstream BCA moiety. In addition, the carboxamide 
oxygen makes a direct and a solvent-mediated hydrogen bond with N510Nδ2 and Y512Oη, respectively. The aro-
matic phenyl ring of the MPA moiety hydrophobically interacts with I478—which explains why this residue has 
disallowed main-chain conformation angles—and, intramolecularly, with the benzyl group of the BCA moiety.
The LYS group of KYT-36 simulates a substrate residue in P1 and thus matches the specificity of the enzyme19. 
Its side chain penetrates the specificity pocket and its aliphatic part is pinched between W513, A451 and C476 
through hydrophobic interactions. The terminal ε-amino group is tetrahedrally bound by D516Oδ2 through a salt 
bridge, by N475O and T442Oγ1 through direct hydrogen bonds, and by Y517N and W513O through hydrogen bonds 
mediated by a solvent molecule (Fig. 2E). The interactions made by T442 and H444 to bind the inhibitor also explain 
why intermediate residue A443 has disallowed main-chain conformation angles. Further downstream, the BCA 
moiety possibly occupies the S1’ sub-site and its amide nitrogen is hydrogen-bonded to G445O. In addition, the 
benzyl group establishes hydrophobic interactions with A451 and H444.
The LYS carbonyl emulates the scissile carbonyl of a substrate and its oxygen is tightly bound by C477N and 
G445N, which play the role of an oxyanion hole35 in Kgp to stabilize the tetrahedral reaction intermediate. The 
carbonyl carbon is just 2.02 Å apart (2.00 Å and 2.03 Å in the two Kgp molecules A and B found in the asymmet-
ric unit of the crystal, respectively) from catalytic C477Sγ, which is roughly perpendicular to the carbon and its 
three bound atoms (Fig. 2D). This distance is larger than a standard aliphatic single C-S bond (1.82 Å;37) and the 
covalent bond found in the 1.75 Å-resolution structure of Kgp with a lysylmethyl group (1.84 Å; Protein Data 
Bank access code [PDB] 4RBM;30). However, the distance is shorter than that reported for reaction-intermediate 
mimics of serine endopeptidases in complex with protein inhibitors (2.6 Å for the complex between trypsin 
and bovine pancreatic trypsin inhibitor;38) and also than the sum of the van-der-Waals radii of carbon and 
sulfur (3.50 Å;39). In addition, the inhibitor carbonyl carbon is pyramidalized, i.e. not coplanar with its three 
bound atoms but shifted towards a tetrahedral configuration. This is reflected by angles C477Sγ-LYS(C)-LYS(O), 
C477Sγ-LYS(C)-LYS(Cα) and C477Sγ-LYS(C)-BCA(C) spanning on average 109.9°, 103.4° and 99.9°, respectively, 
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Figure 2. Interactions of the Kgp·KYT-36 complex. (A) Ribbon plot of Kgp, which mimics a tooth, whose crown 
encompasses the cusp in the top and consists of the NSD (blue ribbon) and CSD domains (magenta ribbon). 
Domain IgSF (grey ribbon) features the tooth root. KYT-36 is displayed as yellow sticks for reference. (B) 
Close-up of the tooth cusp encompassing the active site. The cleft runs from left (non-primed sub-sites) to right 
(primed sub-sites). Only the CSD is displayed as a plum ribbon for clarity. Kgp residues relevant for the complex 
are shown for their side chains (carbons in sandy brown) and labeled. The proposed catalytic triad is C477, H444 
and D388 30. Solvent molecules and structural sodium cations are depicted as red and blue spheres, respectively. 
KYT-36 is shown as a stick model with carbons in light blue. (C) Structure of KYT-36 and Kgp catalytic residue 
C477 superposed with a (2mFobs-DFcalc)-type Fourier map contoured at 0.8σ (left) and after a 90°-rotation (right). 
The five moieties of the inhibitor (see Fig. 1) are labeled. The inset in the top left depicts the chemical structure of 
the inhibitor for reference. (D) Detail of (C, left) after reorientation depicting the pseudo-covalent bond (2.02 Å) 
between C477Sγ (yellow arrow) and the carbonyl carbon of LYS (blue arrow), which mimics the scissile carbonyl 
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instead of 90°. Thus, the present structure simulates a state immediately previous to formation of the tetrahedral 
reaction intermediate of the nucleophilic addition.
Conclusions. The complex structure of Kgp with its specific inhibitor KYT-36 revealed that the 
sub-nanomolar inhibition exerted by the inhibitor is based on 24 intermolecular interactions and the fact that the 
active-site cleft of the enzyme is blocked from sub-sites S3 to S1’. The side chain of inhibitor moiety LYS penetrates 
the S1 pocket like a substrate and makes four hydrogen bonds and a salt bridge, in addition to hydrophobic inter-
actions with three protein residues.
The complex is also a valid model for the state preceding the formation of the tetrahedral reaction interme-
diate of the nucleophilic attack of C477Sγ onto the scissile carbonyl carbon during catalysis. This is reminiscent 
of structures of complexes between serine endopeptidases and protein inhibitors. In either case, the distances 
between the catalytic nucleophile and the scissile-carbonyl-carbon-mimic are larger than a regular bond but too 
short for a van-der-Waals interaction. Moreover, the carbon is pyramidalized, i.e. in a state preceding the tetra-
hedral intermediate.
Finally, the present data will foster the development of novel specific drugs against a major virulence factor 
of P. gingivalis, which may add to the locally-applied therapeutic agents currently used for PD as adjuncts to 
non-surgical therapy22. These adjuncts include doxycycline and minocycline, which are tetracycline antibiotics 
that inhibit host matrix metalloproteinases at doses low enough not to have antimicrobial activity. In this way, 
they do not select for antibiotic resistance within bacteria40. The potential of KYT-36 to contribute to such a 
development was demonstrated recently by KYT-41. This is a further development of KYT-36 and KYT-1, which 
potently and selectively blocks both Kgp (Ki = 2.7 × 10−10 M) and RgpA/B (Ki = 4.0 × 10−8 M), and shows thera-
peutic potential in guinea pig and dog models21.
Experimental Procedures
Protein production and complex formation. A Kgp construct spanning the CD and IgSF domains from 
P. gingivalis strain W83 (sequence D229-P683; UniProt (UP) entry Q51817) and a C-terminal His6-tag was purified 
from culture medium of P. gingivalis mutant strain ABM1 by affinity chromatography on Nickel-Sepharose beads 
as previously described41,42. The resulting sample was first incubated with Nα-tosyl-L-lysinylchloromethane 
(Sigma) prior to elution from the beads to avoid autolysis and then with excess of KYT-36 (purchased from 
Peptide International, KY, USA). The final complex was concentrated to ~10 mg/ml in 5 mM Tris·HCl pH 8, 
150 mM sodium chloride, 0.02% sodium azide, 1 mM 1,4-dithiothreitol (DTT) for crystallization.
Crystallization and diffraction data collection. Crystallization assays were performed by the 
sitting-drop vapor diffusion method. Reservoir solutions were prepared with a Tecan robot and 100-nL crys-
tallization drops were dispensed on 96 × 2-well MRC nanoplates (Innovadyne) by a Phoenix nanodrop robot 
(Art Robbins) or a Cartesian Microsys 4000 XL (Genomic Solutions) robot at the IBMB-IRB joint Automated 
Crystallography Platform at Barcelona Science Park. Plates were stored in Bruker steady-temperature crystal 
farms at 4 °C or 20 °C. Successful conditions were scaled up to the microliter range in 24-well Cryschem crystal-
lization dishes (Hampton Research). The best Kgp·KYT-36 complex crystals were obtained at 20 °C with protein 
solution and 20% polyethylene glycol 8000, 0.1 M HEPES pH 7.5 as reservoir solution from 1 μL: 1 μL drops. 
Crystals were cryo-protected by immersion in harvesting solution containing reservoir solution plus 20% glyc-
erol. Diffraction data were collected at 100 K from liquid-N2 flash cryo-cooled crystals (Oxford Cryosystems 700 
series cryostream) on a Pilatus 6 M pixel detector (Dectris) at beam line XALOC43 of the ALBA synchrotron in 
Cerdanyola (Catalonia, Spain). These data were processed with programs XDS44 and XSCALE45, and transformed 
with XDSCONV to formats suitable for the CCP4 suite of programs46. Given that cell constants a and b were 
very similar (86.66 Å and 87.05 Å, respectively), initial indexation suggested a tetragonal setting. This was proven 
wrong during integration and merging of the reflections, which revealed that the crystals actually belonged to a 
primitive orthorhombic space group with two peptidase·inhibitor complexes per asymmetric unit.
Structure solution and refinement. The structure of Kgp·KYT-36 was solved by likelihood-scoring molec-
ular replacement with the PHASER47 program using the coordinates of the protein part of Kgp crystallized in a dif-
ferent unit cell (PDB 4RBM;30) and diffraction data processed to 1.25 Å resolution. Two solutions were obtained at 
final Eulerian angles (α, β, γ, in °) 188.9, 71.0, 312.8 and 287.3, 71.3, 313.9; and fractional cell coordinates (x, y, z) 
0.472, −0.103, 0.293 and −0.209, −0.295, 0.529, respectively. The initial values for the rotation/translation func-
tion Z-scores were 7.4/8.0 and 7.7/9.0, respectively, and the final log-likelihood gain was 62,873. These calcula-
tions revealed that P212121 was the correct space group. Subsequently, an automatic tracing step with ARP/wARP48 
yielded a model, which was completed through successive rounds of manual model building with the COOT 
program49 and crystallographic refinement with the PHENIX50 and BUSTER/TNT51 programs, which included 
TLS refinement. In the final stages, anisotropic B-factor and alternate occupancy refinement was performed with 
BUSTER/TNT using data reprocessed to 1.20 Å resolution (see Table 1 for data processing statistics). The final 
model contained residues D229-G681, two calcium and two sodium cations, two unknown atoms/ions (UNK), and 
one KYT-36 moiety for each of the two Kgp molecules in the asymmetric unit. Further one DTT, six glycerols, 
two HEPES, and 1,580 solvent molecules completed the final model. The HEPES molecules were only tentatively 
carbon of a substrate and is pyramidalized. (E) Scheme with the average distance values of direct (green) and 
solvent-mediated (blue) hydrogen bonds, salt bridges (red), hydrophobic interactions (orange), and the pseudo-
covalent bond between the LYS carbonyl carbon (purple arrow) and catalytic C477Sγ (grey).
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assigned based on poor density and show two positions. Three residues of each molecule (A443, I478 and I576) 
were in disallowed regions of the Ramachandran plot but were unambiguously resolved in the final Fourier map. 
Three proline residues were found in cis conformation (P241, P424, and P453). Table 1 provides refinement and 
model validation statistics.
Once the structure was solved, the two molecules in the asymmetric unit were found to be related by 
a pure non-crystallographic twofold parallel to (1 1 0). Upon superposition of the protein moieties, the two 
inhibitor molecules perfectly matched and were engaged in crystal contacts with segment Y389-Q394 from the 
non-crystallographic symmetry mate. These contacts are very similar but not identical, which might actually have 
given rise to rupture of the tetragonal symmetry suggested by the indexation procedure.
Miscellaneous. Ideal coordinates and parameters for crystallographic refinement of KYT-36 were obtained 
from the PRODRG server52. Structure figures were prepared with the CHIMERA program53. The model was 
validated with the wwPDB Validation Server (https://www.wwpdb.org/validation;)54. The final coordinates of P. 
gingivalis Kgp·KYT-36 are deposited with the PDB at www.pdb.org (access code 6I9A).
References
 1. Wade, W. G. The oral microbiome in health and disease. Pharmacol. Res. 69, 137–143 (2013).
 2. Human Microbiome Project, Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
 3. Haenel, H., Schmidt, E. F. & Feldheim, G. Fäkale Dysbiose im Säuglingsalter [Fecal dysbiosis in infancy]. Z. Kinderheilkd. 82, 
595–603 (1959).
 4. Lamont, R. J. & Hajishengallis, G. Polymicrobial synergy and dysbiosis in inflammatory disease. Trends Mol. Med. 21, 172–183 
(2015).
 5. Kassebaum, N. J. et al. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. J. Dent. Res. 93, 
1045–1053 (2014).
 6. Potempa, J., Mydel, P. & Koziel, J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 
606–620 (2017).
 7. Socransky, S. S., Haffajee, A. D., Cugini, M. A., Smith, C. & Kent, R. L. Jr. Microbial complexes in subgingival plaque. J. Clin. 
Periodontol. 25, 134–144 (1998).
 8. Hajishengallis, G. et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal 
microbiota and complement. Cell Host & Microbe 10, 497–506 (2011).
 9. Potempa, J. & Travis, J. Porphyromonas gingivalis proteinases in periodontitis, a review. Acta Biochim. Pol. 43, 455–465 (1996).




Cell constants (a, b, c, in Å) 86.67, 87.05, 129.21
Wavelength (Å) 0.97949
No. of measurements/unique reflections 2,922,120/290,672
Resolution range (Å) 72.2 – 1.20 (1.27 – 1.20)a
Completeness (%) 95.8 (75.2)
Rmerge 0.065 (0.726)
Rmeas/CC1/2 0.068 (0.800)/1.000 (0.843)
<I/σ(I)> of unique reflections after merging 19.6 (2.9)
B-Factor (Wilson) (Å2)/Aver. Multiplicity 15.9/10.1 (5.2)
Structure refinement
Resolution range used for refinement (Å) 72.2 – 1.20
No. of reflections used (test set) 289,551 (1120)
Crystallographic Rfactor (free Rfactor) 0.146 (0.148)b
No. of protein residues + atoms/solvent molecules/ligandsc 906 + 7,048/1,580/2 K36, 4 Ca
2+, 4 
Na+, 4 UNK, 1 DTT, 6 GOL, 2 EPE
Correlation coefficient Fobs-Fcalc 0.962b
Rmsd from target valuesb
   bonds (Å)/angles (°) 0.012/1.17
Average B-factors (Å2) (all// molec. A/B) 16.3//13.2/13.3
Overall anisotropic B-value (B11, B22, B33, in Å2) 1.04, −3.67, 2.64
All-atom contacts and geometry analysisd
   Protein residues in favored regions/outliers/all residues 915e (97%)/6f/947e
   Protein residues with outlying rotamers/bonds/angles/chirality/planarity 2/0/0/0/0
   All-atom clashscore 2.7
Table 1. Crystallographic data. aData processing values in parenthesis are for the outermost resolution shell. 
bAccording to the final BUSTER/TNT refinement step. cK36, KYT-36; DTT, (2S,3S)-1,4-bis(sulfanyl)butane-
2,3-diol; GOL, glycerol; UNK, unknown atoms/ions; and EPE, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES.). dwwPDB X-ray Structure Validation Report. eIncluding residues with atoms in two positions. 
fAll outliers are unambiguously resolved in the final Fourier map.
7Scientific RepoRts |          (2019) 9:4935  | https://doi.org/10.1038/s41598-019-41354-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
 11. Potempa, J., Sroka, A., Imamura, T. & Travis, J. Gingipains, the major cysteine proteinases and virulence factors of Porphyromonas 
gingivalis: structure, function and assembly of multidomain protein complexes. Curr. Prot. Pept. Sci. 4, 397–407 (2003).
 12. Lasica, A. M., Ksiazek, M., Madej, M. & Potempa, J. The Type IX Secretion System (T9SS): highlights and recent insights into Its 
structure and function. Front. Cell. Infect. Microbiol. 7, 215 (2017).
 13. Lauber, F., Deme, J. C., Lea, S. M. & Berks, B. C. Type 9 secretion system structures reveal a new protein transport mechanism. 
Nature 564, 77–82 (2018).
 14. de Diego, I. et al. The outer-membrane export signal of Porphyromonas gingivalis type IX secretion system (T9SS) is a conserved 
C-terminal β-sandwich domain. Sci. Rep. 6, 23123 (2016).
 15. Guentsch, A. et al. Comparison of gingival crevicular fluid sampling methods in patients with severe chronic periodontitis. J. 
Periodontol. 82, 1051–1060 (2011).
 16. Guo, Y., Nguyen, K. A. & Potempa, J. Dichotomy of gingipains action as virulence factors: from cleaving substrates with the precision 
of a surgeon’s knife to a meat chopper-like brutal degradation of proteins. Periodontol. 2000 54, 15–44 (2010).
 17. Potempa, J., Pike, R. & Travis, J. Titration and mapping of the active site of cysteine proteinases from Porphyromonas gingivalis 
(gingipains) using peptidyl chloromethanes. Biol. Chem. 378, 223–230 (1997).
 18. Pathirana, R. D., O’Brien-Simpson, N. M., Brammar, G. C., Slakeski, N. & Reynolds, E. C. Kgp and RgpB, but not RgpA, are 
important for Porphyromonas gingivalis virulence in the murine periodontitis model. Infect. Immun. 75, 1436–1442 (2007).
 19. Pike, R. N. & Potempa, J. In Handbook of Proteolytic Enzymes Vol. 2 (eds N. D. Rawlings & G. Salvesen) 2337–2344 (Academic Press, 
2013).
 20. Brochu, V., Grenier, D., Nakayama, K. & Mayrand, D. Acquisition of iron from human transferrin by Porphyromonas gingivalis: a 
role for Arg- and Lys-gingipain activities. Oral Microbiol. Immunol. 16, 79–87 (2001).
 21. Kataoka, S. et al. A novel, potent dual inhibitor of Arg-gingipains and Lys-gingipain as a promising agent for periodontal disease 
therapy. FASEB J. 28, 3564–3578 (2014).
 22. Hosn, K. N., Jefferson, M. M., Leding, C., Shokouh-Amiri, S. & Thomas, E. L. Inhibitors of bacterial protease enzymes for 
periodontal therapy. Clin. Exp. Dent. Res. 1, 18–25 (2015).
 23. Haffajee, A. D., Socransky, S. S. & Gunsolley, J. C. Systemic anti-infective periodontal therapy. A systematic review. Ann. Periodontol. 
8, 115–181 (2003).
 24. Dewhirst, F. E. et al. The human oral microbiome. J. Bacteriol. 192, 5002–5017 (2010).
 25. Gómez, A. & Nelson, K. E. The oral microbiome of children: development, disease, and implications beyond oral health. Microb. 
Ecol. 73, 492–503 (2017).
 26. Kadowaki, T. et al. Suppression of pathogenicity of Porphyromonas gingivalis by newly developed gingipain inhibitors. Mol. 
Pharmacol. 66, 1599–1606 (2004).
 27. Liu, Y. et al. Infection of microglia with Porphyromonas gingivalis promotes cell migration and an inflammatory response through 
the gingipain-mediated activation of protease-activated receptor-2 in mice. Sci. Rep. 7, 11759 (2017).
 28. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 257, 1078–1082 (1992).
 29. Mittl, P. R. & Grütter, M. G. Opportunities for structure-based design of protease-directed drugs. Curr. Opin. Struct. Biol. 16, 
769–775 (2006).
 30. de Diego, I. et al. Structure and mechanism of cysteine peptidase gingipain K (Kgp), a major virulence factor of Porphyromonas 
gingivalis in periodontitis. J. Biol. Chem. 289, 32291–32302 (2014).
 31. Pomowski, A. et al. Structural insights unravel the zymogenic mechanism of the virulence factor gingipain K from Porphyromonas 
gingivalis, a causative agent of gum disease from the human oral microbiome. J. Biol. Chem. 292, 5724–5735 (2017).
 32. Ollis, D. L. et al. The α/β hydrolase fold. Prot. Eng. 5, 197–211 (1992).
 33. Guarné, A. et al. Structural and biochemical features distinguish the foot-and-mouth disease virus leader proteinase from other 
papain-like enzymes. J. Mol. Biol. 302, 1227–1240 (2000).
 34. Pavloff, N. et al. Molecular cloning and characterization of Porphyromonas gingivalis lysine-specific gingipain. A new member of an 
emerging family of pathogenic bacterial cysteine proteinases. J. Biol. Chem. 272, 1595–1600 (1997).
 35. Polgár, L. In Handbook of Proteolytic Enzymes Vol. 2 (eds N. D. Rawlings & G. S. Salvesen) 1773–1784 (Academic Press, 2013).
 36. Schechter, I. & Berger, A. On the size of active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162 (1967).
 37. Sutton, L. E. E. Tables of interatomic distances and configuration in molecules and ions (Supplement 1956–1959). (The Chemical 
Society, 1965).
 38. Huber, R. & Bode, W. Structural basis of the activation and action of trypsin. Acc. Chem. Res. 11, 114–122 (1978).
 39. Bondi, A. Van der Waals volumes and radii. J. Phys. Chem. 68, 441–451 (1964).
 40. Caton, J. & Ryan, M. E. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline 
(SDD). Pharmacol. Res. 63, 114–120 (2011).
 41. Potempa, J. & Nguyen, K. A. Purification and characterization of gingipains. Curr. Protoc. Prot. Sci. Suppl. 49, 21.20.21–21.20.27 
(2007).
 42. Sztukowska, M. et al. Disruption of gingipain oligomerization into non-covalent cell-surface attached complexes. Biol. Chem. 393, 
971–977 (2012).
 43. Juanhuix, J. et al. Developments in optics and performance at BL13-XALOC, the macromolecular crystallography beamline at the 
ALBA synchrotron. J. Synchrotron Radiat. 21, 679–689 (2014).
 44. Kabsch, W. XDS. Acta Crystallogr. sect. D 66, 125–132 (2010).
 45. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. sect. D 66, 133–144 (2010).
 46. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. sect. D 67, 235–242 (2011).
 47. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
 48. Langer, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. Automated macromolecular model building for X-ray crystallography using 
ARP/wARP version 7. Nat. Protoc. 3, 1171–1179 (2008).
 49. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. sect. D 66, 486–501 (2010).
 50. Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. sect. D 68, 
352–367 (2012).
 51. Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta 
Crystallogr. sect. D 68, 368–380 (2012).
 52. Schüttelkopf, A. W. & van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta 
Crystallogr. sect. D 60, 1355–1363 (2004).
 53. Pettersen, E. F. et al. UCSF Chimera - A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 
(2004).
 54. Berman, H., Henrick, K. & Nakamura, H. Announcing the worldwide Protein Data Bank. Nat. Struct. Biol. 10, 980–980 (2003).
8Scientific RepoRts |          (2019) 9:4935  | https://doi.org/10.1038/s41598-019-41354-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
We are grateful to Joan Pous and Xandra Kreplin from the joint IBMB/IRB Automated Crystallography Platform 
and to Roman Bonet from the Protein Purification Facility at IBMB for assistance. We further acknowledge the 
help of local contacts provided by the ALBA synchrotron. This study was supported in part by grants from US 
American (NIH/NIDCR R01 DE022597), Polish (National Science Center and Ministry of Science and Higher 
Education, Miniatura 2017/01/X/NZ1/01378, UMO-2015/199/N/NZ1/00322, UMO-2015/17/B/NZ1/00666, 
UMO-2016/21/B/NZ1/00292, and Mobility Plus 1306/MOB/IV/2015/0), Spanish (BFU2015-64487R and 
MDM-2014-0435), and Catalan (2017SGR3, and Fundació “La Marató de TV3” 201815) agencies. The Structural 
Biology Unit (www.sbu.csic.es) of IBMB is a “María de Maeztu” Unit of Excellence from the Spanish Ministry of 
Science, Innovation and Universities.
Author Contributions
F.X.G.R. and J.P. conceived the work; A.M.L., M.K. and B.P. produced and purified the protein; T.G., A.R.B. and 
F.X.G.R. performed crystallization and structural studies; F.X.G.R. and J.P. wrote the paper with contributions 
from all authors.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
